| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Outsourcing > Outsourced Product Development - Rising Phenomenon |
|
Just Other Articles - Outsourced Product Development - Rising Phenomenon
Outsourcing today is no longer seen as an option only for repetitive, non-innovative, and non-strategic functions; it is increasingly bei According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ng evaluated and regarded as a viable option for more strategic business functions. One such area that has seen new and growing interest ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in in outsourcing is outsourced
product development. In the backdrop of speedily changing business environment, stiff competition lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. and declining market shares, companies have been challenged to expand into new
markets, introduce new and innovative products, and app here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe y the latest product development technology to their development work. In such highly competitive environment, time to market ha d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro become the critical differentiator. Companies’ efforts to achieve better time to market have, however, been challenged by following facto ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc s:
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi gies
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically tion to product development The cited challenges and the more pressing requirements to innovate and introduce new products hav and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ only caused product development costs to shoot up further. Consequently, companies have recognized quickly that working with th ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi rd party specialists through an outsourcing engagement can help them reduce design cycle times, achieve better time to market, reduce co ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ts, minimize risks, access the latest technology without owning it, improve return on their product development investment, and, in the p dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ocess, improve the overall competitiveness of their products. Major outsourcing driving factors:
cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin cy
tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen >
t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ariability
Bottom ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust Line Today, outsourcing is no longer seen as an option only for repetitive, non-innovative, and non-strategic functions; it is inc y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products easingly being evaluated and regarded as a viable option for more strategic business functions.Factors such as cost efficiency, focus on c . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de re business, access to technology, time to market, access to global expertise, among others are the reasons for elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ://www.outworx.com"> outsource product development that leverage quality and development discipline to the product as well. tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Need Temporary Office Space... But Don't Have A Big Budget? Real Estate Postcard Q&A: What Headlines Work Best?
|